Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Conference Coverage (AACR)
Tri-Partner Protocol Enhances Vaccine Antitumor Immunity
May 26th, 1997
In vivo antitumor immunity is enhanced by a protocol combining interleukin 12 (IL-12) expressing fibroblasts, costimulatory molecules expressing fibroblasts, and parental tumor cells. Researchers from the Centre Claudius Regaud, France, and the University of Pittsburgh, Pennsylvania, have enhanced the anticancer immune stimulating effect of the costimulatory molecule B7.1 by creating a three-way vaccine. Results from in vivo experiments with this tri partner vaccine were presented by V. Doin-Echinard at the American Association for Cancer Research conference, held April 12-16, 1997, in San Diego, California. "We have shown here the [potential] of...
Source: Cancer Weekly (1997-05-26)
|
